ID   BAX_HUMAN               Reviewed;         192 AA.
AC   Q07812; A8K4W1; P55269; Q07814; Q07815; Q8WZ49; Q9NR76; Q9NYG7;
AC   Q9UCZ6; Q9UCZ7; Q9UQD6;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   22-JUL-2015, entry version 170.
DE   RecName: Full=Apoptosis regulator BAX;
DE   AltName: Full=Bcl-2-like protein 4;
DE            Short=Bcl2-L-4;
GN   Name=BAX; Synonyms=BCL2L4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), FUNCTION,
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RC   TISSUE=B-cell;
RX   PubMed=8358790; DOI=10.1016/0092-8674(93)90509-O;
RA   Oltvai Z.N., Milliman C.L., Korsmeyer S.J.;
RT   "Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
RT   accelerates programmed cell death.";
RL   Cell 74:609-619(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA).
RX   PubMed=7607685; DOI=10.1016/0888-7543(95)80180-T;
RA   Apte S.S., Mattei M.-G., Olsen B.R.;
RT   "Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and
RT   isolation of a novel alternatively spliced transcript, BAX delta.";
RL   Genomics 26:592-594(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EPSILON).
RC   TISSUE=Brain;
RX   PubMed=9920818; DOI=10.1006/bbrc.1998.0130;
RA   Shi B., Triebe D., Kajiji S., Iwata K.K., Bruskin A., Mahajna J.;
RT   "Identification and characterization of baxepsilon, a novel bax
RT   variant missing the BH2 and the transmembrane domains.";
RL   Biochem. Biophys. Res. Commun. 254:779-785(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND SIGMA), FUNCTION,
RP   INTERACTION WITH BCL2A1 AND BCL2L1, AND TISSUE SPECIFICITY.
RX   PubMed=10772918; DOI=10.1006/bbrc.2000.2537;
RA   Schmitt E., Paquet C., Beauchemin M., Dever-Bertrand J., Bertrand R.;
RT   "Characterization of Bax-sigma, a cell death-inducing isoform of
RT   Bax.";
RL   Biochem. Biophys. Res. Commun. 270:868-879(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSI), AND TISSUE SPECIFICITY.
RX   PubMed=11912183; DOI=10.1093/hmg/11.6.675;
RA   Cartron P.F., Oliver L., Martin S., Moreau C., LeCabellec M.T.,
RA   Jezequel P., Meflah K., Vallette F.M.;
RT   "The expression of a new variant of the pro-apoptotic molecule Bax,
RT   Baxpsi, is correlated with an increased survival of glioblastoma
RT   multiforme patients.";
RL   Hum. Mol. Genet. 11:675-687(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZETA).
RC   TISSUE=Ovarian carcinoma;
RA   Perez R.P., Sanville H.;
RT   "Bax mRNA splice variant lacking exons 2 and 3.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 63-77 AND 98-118, AND VARIANTS ARG-67
RP   AND VAL-108.
RX   PubMed=7475270;
RA   Meijerink J.P.P., Smetsers T.F.C.M., Sloetjes A.W., Linders E.H.P.,
RA   Mensink E.J.B.M.;
RT   "Bax mutations in cell lines derived from hematological
RT   malignancies.";
RL   Leukemia 9:1828-1832(1995).
RN   [12]
RP   MUTAGENESIS, AND FUNCTION OF BH3 MOTIF.
RX   PubMed=8521816;
RA   Chittenden T., Flemington C., Houghton A.B., Ebb R.G., Gallo G.J.,
RA   Elangovan B., Chinnadurai G., Lutz R.J.;
RT   "A conserved domain in Bak, distinct from BH1 and BH2, mediates cell
RT   death and protein binding functions.";
RL   EMBO J. 14:5589-5596(1995).
RN   [13]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-184.
RX   PubMed=10228148; DOI=10.1093/emboj/18.9.2330;
RA   Nechushtan A., Smith C.L., Hsu Y.-T., Youle R.J.;
RT   "Conformation of the Bax C-terminus regulates subcellular location and
RT   cell death.";
RL   EMBO J. 18:2330-2341(1999).
RN   [14]
RP   INTERACTION WITH SH3GLB1.
RX   PubMed=11259440; DOI=10.1074/jbc.M101527200;
RA   Cuddeback S.M., Yamaguchi H., Komatsu K., Miyashita T., Yamada M.,
RA   Wu C., Singh S., Wang H.-G.;
RT   "Molecular cloning and characterization of Bif-1. A novel Src homology
RT   3 domain-containing protein that associates with Bax.";
RL   J. Biol. Chem. 276:20559-20565(2001).
RN   [15]
RP   INTERACTION WITH HN.
RX   PubMed=12732850; DOI=10.1038/nature01627;
RA   Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C.,
RA   Reed J.C.;
RT   "Humanin peptide suppresses apoptosis by interfering with Bax
RT   activation.";
RL   Nature 423:456-461(2003).
RN   [16]
RP   INTERACTION WITH SFN AND YWHAZ, AND SUBCELLULAR LOCATION.
RX   PubMed=15071501; DOI=10.1038/sj.emboj.7600194;
RA   Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S.,
RA   Tsujimoto Y., Yoshioka K., Masuyama N., Gotoh Y.;
RT   "JNK promotes Bax translocation to mitochondria through
RT   phosphorylation of 14-3-3 proteins.";
RL   EMBO J. 23:1889-1899(2004).
RN   [17]
RP   INTERACTION WITH NOL3.
RX   PubMed=15004034; DOI=10.1074/jbc.M400695200;
RA   Gustafsson A.B., Tsai J.G., Logue S.E., Crow M.T., Gottlieb R.A.;
RT   "Apoptosis repressor with caspase recruitment domain protects against
RT   cell death by interfering with Bax activation.";
RL   J. Biol. Chem. 279:21233-21238(2004).
RN   [18]
RP   INTERACTION WITH HHV-5 PROTEIN UL37.
RX   PubMed=15004026; DOI=10.1074/jbc.M308408200;
RA   Poncet D., Larochette N., Pauleau A.L., Boya P., Jalil A.A.,
RA   Cartron P.F., Vallette F., Schnebelen C., Bartle L.M., Skaletskaya A.,
RA   Boutolleau D., Martinou J.C., Goldmacher V.S., Kroemer G., Zamzami N.;
RT   "An anti-apoptotic viral protein that recruits Bax to mitochondria.";
RL   J. Biol. Chem. 279:22605-22614(2004).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CLU.
RX   PubMed=16113678; DOI=10.1038/ncb1291;
RA   Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.Y.;
RT   "Clusterin inhibits apoptosis by interacting with activated Bax.";
RL   Nat. Cell Biol. 7:909-915(2005).
RN   [20]
RP   INTERACTION WITH FAIM2/LFG2.
RX   PubMed=16964429;
RA   Reimers K., Choi C.Y., Mau-Thek E., Vogt P.M.;
RT   "Sequence analysis shows that Lifeguard belongs to a new
RT   evolutionarily conserved cytoprotective family.";
RL   Int. J. Mol. Med. 18:729-734(2006).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [22]
RP   INTERACTION WITH RNF144B.
RX   PubMed=20300062; DOI=10.1038/emboj.2010.39;
RA   Benard G., Neutzner A., Peng G., Wang C., Livak F., Youle R.J.,
RA   Karbowski M.;
RT   "IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for
RT   Bax and apoptosis activation.";
RL   EMBO J. 29:1458-1471(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   INTERACTION WITH BOP/C22ORF29.
RX   PubMed=23055042; DOI=10.1007/s13238-012-2069-7;
RA   Zhang X., Weng C., Li Y., Wang X., Jiang C., Li X., Xu Y., Chen Q.,
RA   Pan L., Tang H.;
RT   "Human Bop is a novel BH3-only member of the Bcl-2 protein family.";
RL   Protein Cell 3:790-801(2012).
RN   [25]
RP   STRUCTURE BY NMR, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=11106734; DOI=10.1016/S0092-8674(00)00167-7;
RA   Suzuki M., Youle R.J., Tjandra N.;
RT   "Structure of Bax: coregulation of dimer formation and intracellular
RT   localization.";
RL   Cell 103:645-654(2000).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-19 IN COMPLEX WITH
RP   ANTIBODY FRAGMENT.
RX   PubMed=16946732; DOI=10.1038/sj.cdd.4402025;
RA   Peyerl F.W., Dai S., Murphy G.A., Crawford F., White J., Marrack P.,
RA   Kappler J.W.;
RT   "Elucidation of some Bax conformational changes through
RT   crystallization of an antibody-peptide complex.";
RL   Cell Death Differ. 14:447-452(2007).
RN   [27]
RP   STRUCTURE BY NMR IN COMPLEX WITH BCL2L11, FUNCTION, SUBUNIT,
RP   MUTAGENESIS OF LYS-21, AND INTERACTION WITH BCL2L11.
RX   PubMed=18948948; DOI=10.1038/nature07396;
RA   Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H.,
RA   Katz S.G., Tu H.C., Kim H., Cheng E.H., Tjandra N., Walensky L.D.;
RT   "BAX activation is initiated at a novel interaction site.";
RL   Nature 455:1076-1081(2008).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 48-81 IN COMPLEXES WITH
RP   BCL2L1 AND MCL1, INTERACTION WITH MCL1; BCL2; BCL2L1 AND BCL2L2,
RP   FUNCTION, AND MUTAGENESIS OF MET-74.
RX   PubMed=21199865; DOI=10.1074/jbc.M110.161281;
RA   Czabotar P.E., Lee E.F., Thompson G.V., Wardak A.Z., Fairlie W.D.,
RA   Colman P.M.;
RT   "Mutation to Bax beyond the BH3 domain disrupts interactions with pro-
RT   survival proteins and promotes apoptosis.";
RL   J. Biol. Chem. 286:7123-7131(2011).
RN   [29]
RP   VARIANTS GLU-11; ARG-67 AND VAL-108.
RX   PubMed=9531611;
RA   Meijerink J.P.P., Mensink E.J.B.M., Wang K., Sedlak T.W.,
RA   Sloetjes A.W., de Witte T., Waksman G., Korsmeyer S.J.;
RT   "Hematopoietic malignancies demonstrate loss-of-function mutations of
RT   BAX.";
RL   Blood 91:2991-2997(1998).
CC   -!- FUNCTION: Accelerates programmed cell death by binding to, and
CC       antagonizing the apoptosis repressor BCL2 or its adenovirus
CC       homolog E1B 19k protein. Under stress conditions, undergoes a
CC       conformation change that causes translocation to the mitochondrion
CC       membrane, leading to the release of cytochrome c that then
CC       triggers apoptosis. Promotes activation of CASP3, and thereby
CC       apoptosis. {ECO:0000269|PubMed:10772918,
CC       ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:18948948,
CC       ECO:0000269|PubMed:21199865, ECO:0000269|PubMed:8358790,
CC       ECO:0000269|PubMed:8521816}.
CC   -!- SUBUNIT: Homodimer. Forms higher oligomers under stress
CC       conditions. Interacts with BCL2L11. Interaction with BCL2L11
CC       promotes BAX oligomerization and association with mitochondrial
CC       membranes, with subsequent release of cytochrome c. Forms
CC       heterodimers with BCL2, E1B 19K protein, BCL2L1 isoform Bcl-X(L),
CC       BCL2L2, MCL1 and A1. Interacts with SH3GLB1 and HN. Interacts with
CC       SFN and YWHAZ; the interaction occurs in the cytoplasm. Under
CC       stress conditions, JNK-mediated phosphorylation of SFN and YWHAZ,
CC       releases BAX to mitochondria. Isoform Sigma interacts with BCL2A1
CC       and BCL2L1 isoform Bcl-X(L). Interacts with RNF144B, which
CC       regulates the ubiquitin-dependent stability of BAX. Interacts with
CC       CLU under stress conditions that cause a conformation change
CC       leading to BAX oligomerization and association with mitochondria.
CC       Does not interact with CLU in unstressed cells. Interacts with
CC       FAIM2/LFG2. Interacts with human cytomegalovirus/HHV-5 protein
CC       vMIA/UL37. Interacts with BOP/C22orf29. Interacts (via a C-
CC       terminal 33 residues) with NOL3 (via CARD domain); inhibits BAX
CC       activation and translocation and consequently cytochrome c release
CC       from mitochondria. {ECO:0000269|PubMed:10772918,
CC       ECO:0000269|PubMed:11106734, ECO:0000269|PubMed:11259440,
CC       ECO:0000269|PubMed:12732850, ECO:0000269|PubMed:15004026,
CC       ECO:0000269|PubMed:15004034, ECO:0000269|PubMed:15071501,
CC       ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:16946732,
CC       ECO:0000269|PubMed:16964429, ECO:0000269|PubMed:18948948,
CC       ECO:0000269|PubMed:20300062, ECO:0000269|PubMed:21199865,
CC       ECO:0000269|PubMed:23055042, ECO:0000269|PubMed:8358790}.
CC   -!- INTERACTION:
CC       Self; NbExp=27; IntAct=EBI-516580, EBI-516580;
CC       P26662:- (xeno); NbExp=3; IntAct=EBI-516580, EBI-9099462;
CC       Q16611:BAK1; NbExp=5; IntAct=EBI-516580, EBI-519866;
CC       P10415:BCL2; NbExp=9; IntAct=EBI-516580, EBI-77694;
CC       Q07817:BCL2L1; NbExp=4; IntAct=EBI-516580, EBI-78035;
CC       Q07817-1:BCL2L1; NbExp=13; IntAct=EBI-516580, EBI-287195;
CC       O43521:BCL2L11; NbExp=19; IntAct=EBI-516580, EBI-526406;
CC       Q92843:BCL2L2; NbExp=3; IntAct=EBI-516580, EBI-707714;
CC       P55957:BID; NbExp=16; IntAct=EBI-516580, EBI-519672;
CC       P70444:Bid (xeno); NbExp=2; IntAct=EBI-516580, EBI-2128640;
CC       O75460:ERN1; NbExp=2; IntAct=EBI-516580, EBI-371750;
CC       Q07820:MCL1; NbExp=6; IntAct=EBI-516580, EBI-1003422;
CC       P97287:Mcl1 (xeno); NbExp=2; IntAct=EBI-516580, EBI-707292;
CC       Q9ULZ3:PYCARD; NbExp=7; IntAct=EBI-516580, EBI-751215;
CC       Q7Z419:RNF144B; NbExp=5; IntAct=EBI-516580, EBI-2129982;
CC       Q9Y371-1:SH3GLB1; NbExp=2; IntAct=EBI-516580, EBI-5291808;
CC       P49334:TOM22 (xeno); NbExp=3; IntAct=EBI-516580, EBI-12527;
CC       P23644:TOM40 (xeno); NbExp=2; IntAct=EBI-516580, EBI-12539;
CC       P24391:tom40 (xeno); NbExp=2; IntAct=EBI-516580, EBI-1791540;
CC       P07213:TOM70 (xeno); NbExp=2; IntAct=EBI-516580, EBI-12551;
CC       Q9P2Y5:UVRAG; NbExp=6; IntAct=EBI-516580, EBI-2952704;
CC       P17361:VACWR028 (xeno); NbExp=3; IntAct=EBI-516580, EBI-7115640;
CC       P12956:XRCC6; NbExp=2; IntAct=EBI-516580, EBI-353208;
CC   -!- SUBCELLULAR LOCATION: Isoform Alpha: Mitochondrion membrane;
CC       Single-pass membrane protein. Cytoplasm. Note=Colocalizes with 14-
CC       3-3 proteins in the cytoplasm. Under stress conditions, undergoes
CC       a conformation change that causes release from JNK-phosphorylated
CC       14-3-3 proteins and translocation to the mitochondrion membrane.
CC   -!- SUBCELLULAR LOCATION: Isoform Beta: Cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform Gamma: Cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform Delta: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=Alpha;
CC         IsoId=Q07812-1; Sequence=Displayed;
CC       Name=Beta;
CC         IsoId=Q07812-2, Q07814-1;
CC         Sequence=VSP_031237;
CC       Name=Gamma;
CC         IsoId=Q07812-3, Q07815-1;
CC         Sequence=VSP_031234, VSP_031236;
CC       Name=Delta;
CC         IsoId=Q07812-4, P55269-1;
CC         Sequence=VSP_031235;
CC       Name=Epsilon;
CC         IsoId=Q07812-5; Sequence=VSP_031240;
CC       Name=Zeta;
CC         IsoId=Q07812-6; Sequence=VSP_031239;
CC       Name=Psi;
CC         IsoId=Q07812-7; Sequence=VSP_031238;
CC       Name=Sigma;
CC         IsoId=Q07812-8; Sequence=VSP_037475;
CC   -!- TISSUE SPECIFICITY: Expressed in a wide variety of tissues.
CC       Isoform Psi is found in glial tumors. Isoform Alpha is expressed
CC       in spleen, breast, ovary, testis, colon and brain, and at low
CC       levels in skin and lung. Isoform Sigma is expressed in spleen,
CC       breast, ovary, testis, lung, colon, brain and at low levels in
CC       skin. Isoform Alpha and isoform Sigma are expressed in pro-
CC       myelocytic leukemia, histiocytic lymphoma, Burkitt's lymphoma, T-
CC       cell lymphoma, lymphoblastic leukemia, breast adenocarcinoma,
CC       ovary adenocarcinoma, prostate carcinoma, prostate adenocarcinoma,
CC       lung carcinoma, epidermoid carcinoma, small cell lung carcinoma
CC       and colon adenocarcinoma cell lines. {ECO:0000269|PubMed:10772918,
CC       ECO:0000269|PubMed:11912183}.
CC   -!- DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAX
CC       for their pro-apoptotic activity and for their interaction with
CC       anti-apoptotic members of the Bcl-2 family. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/bax/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BAXID128ch19q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L22473; AAA03619.1; -; mRNA.
DR   EMBL; L22474; AAA03620.1; -; mRNA.
DR   EMBL; L22475; AAA03621.1; -; mRNA.
DR   EMBL; U19599; AAC50142.1; -; mRNA.
DR   EMBL; AF007826; AAD22706.1; -; mRNA.
DR   EMBL; AF247393; AAF71267.1; -; mRNA.
DR   EMBL; AJ417988; CAD10744.1; -; mRNA.
DR   EMBL; AF250190; AAF82094.1; -; mRNA.
DR   EMBL; AK291076; BAF83765.1; -; mRNA.
DR   EMBL; AY217036; AAO22992.1; -; Genomic_DNA.
DR   EMBL; CH471177; EAW52418.1; -; Genomic_DNA.
DR   EMBL; CH471177; EAW52417.1; -; Genomic_DNA.
DR   EMBL; BC014175; AAH14175.1; -; mRNA.
DR   CCDS; CCDS12742.1; -. [Q07812-1]
DR   CCDS; CCDS12743.1; -. [Q07812-4]
DR   CCDS; CCDS12744.1; -. [Q07812-2]
DR   CCDS; CCDS12745.2; -. [Q07812-8]
DR   PIR; A47538; A47538.
DR   PIR; B47538; B47538.
DR   PIR; C47538; C47538.
DR   PIR; I38921; I38921.
DR   PIR; JC7255; JC7255.
DR   RefSeq; NP_001278357.1; NM_001291428.1.
DR   RefSeq; NP_001278360.1; NM_001291431.1. [Q07812-6]
DR   RefSeq; NP_004315.1; NM_004324.3. [Q07812-2]
DR   RefSeq; NP_620116.1; NM_138761.3. [Q07812-1]
DR   RefSeq; NP_620118.1; NM_138763.3. [Q07812-4]
DR   RefSeq; NP_620119.2; NM_138764.4. [Q07812-8]
DR   UniGene; Hs.624291; -.
DR   PDB; 1F16; NMR; -; A=1-192.
DR   PDB; 2G5B; X-ray; 2.30 A; I/J/K/L=13-19.
DR   PDB; 2K7W; NMR; -; A=1-192.
DR   PDB; 2LR1; NMR; -; A=1-192.
DR   PDB; 3PK1; X-ray; 2.49 A; B/D=48-81.
DR   PDB; 3PL7; X-ray; 2.61 A; C=48-81.
DR   PDB; 4BD2; X-ray; 2.21 A; A=1-171.
DR   PDB; 4BD6; X-ray; 2.49 A; A=1-171, C=48-81.
DR   PDB; 4BD7; X-ray; 2.80 A; A/B/C/D=1-171.
DR   PDB; 4BD8; X-ray; 2.22 A; A/B/C/D=1-171.
DR   PDB; 4BDU; X-ray; 3.00 A; A/B/C/D=53-128.
DR   PDBsum; 1F16; -.
DR   PDBsum; 2G5B; -.
DR   PDBsum; 2K7W; -.
DR   PDBsum; 2LR1; -.
DR   PDBsum; 3PK1; -.
DR   PDBsum; 3PL7; -.
DR   PDBsum; 4BD2; -.
DR   PDBsum; 4BD6; -.
DR   PDBsum; 4BD7; -.
DR   PDBsum; 4BD8; -.
DR   PDBsum; 4BDU; -.
DR   ProteinModelPortal; Q07812; -.
DR   SMR; Q07812; 1-192.
DR   BioGrid; 107057; 51.
DR   DIP; DIP-232N; -.
DR   IntAct; Q07812; 39.
DR   MINT; MINT-134330; -.
DR   STRING; 9606.ENSP00000293288; -.
DR   ChEMBL; CHEMBL5318; -.
DR   TCDB; 1.A.21.1.2; the bcl-2 (bcl-2) family.
DR   PhosphoSite; Q07812; -.
DR   BioMuta; BAX; -.
DR   DMDM; 728945; -.
DR   MaxQB; Q07812; -.
DR   PaxDb; Q07812; -.
DR   PRIDE; Q07812; -.
DR   DNASU; 581; -.
DR   Ensembl; ENST00000293288; ENSP00000293288; ENSG00000087088. [Q07812-2]
DR   Ensembl; ENST00000345358; ENSP00000263262; ENSG00000087088.
DR   Ensembl; ENST00000354470; ENSP00000346461; ENSG00000087088. [Q07812-4]
DR   Ensembl; ENST00000356483; ENSP00000348871; ENSG00000087088. [Q07812-5]
DR   Ensembl; ENST00000415969; ENSP00000389971; ENSG00000087088. [Q07812-8]
DR   Ensembl; ENST00000515540; ENSP00000426328; ENSG00000087088. [Q07812-3]
DR   GeneID; 581; -.
DR   KEGG; hsa:581; -.
DR   UCSC; uc002plf.1; human. [Q07812-2]
DR   UCSC; uc002plj.3; human. [Q07812-8]
DR   UCSC; uc002plk.3; human. [Q07812-1]
DR   UCSC; uc002pll.3; human. [Q07812-4]
DR   CTD; 581; -.
DR   GeneCards; GC19P049458; -.
DR   HGNC; HGNC:959; BAX.
DR   HPA; CAB004206; -.
DR   HPA; HPA027878; -.
DR   MIM; 600040; gene.
DR   neXtProt; NX_Q07812; -.
DR   PharmGKB; PA25269; -.
DR   eggNOG; NOG46695; -.
DR   GeneTree; ENSGT00730000111112; -.
DR   HOVERGEN; HBG003606; -.
DR   InParanoid; Q07812; -.
DR   KO; K02159; -.
DR   OMA; ADMFADG; -.
DR   PhylomeDB; Q07812; -.
DR   TreeFam; TF315834; -.
DR   Reactome; REACT_584; Activation, translocation and oligomerization of BAX.
DR   ChiTaRS; BAX; human.
DR   EvolutionaryTrace; Q07812; -.
DR   GeneWiki; Bcl-2-associated_X_protein; -.
DR   GenomeRNAi; 581; -.
DR   NextBio; 2371; -.
DR   PMAP-CutDB; Q07812; -.
DR   PRO; PR:Q07812; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; Q07812; -.
DR   CleanEx; HS_BAX; -.
DR   ExpressionAtlas; Q07812; baseline and differential.
DR   Genevisible; Q07812; HS.
DR   GO; GO:0097144; C:BAX complex; IDA:UniProtKB.
DR   GO; GO:0097136; C:Bcl-2 family protein complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HGNC.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:HGNC.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IBA:GO_Central.
DR   GO; GO:0005757; C:mitochondrial permeability transition pore complex; IDA:HGNC.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; IDA:AgBase.
DR   GO; GO:0005634; C:nucleus; IMP:UniProtKB.
DR   GO; GO:0046930; C:pore complex; IDA:BHF-UCL.
DR   GO; GO:0051434; F:BH3 domain binding; IDA:UniProtKB.
DR   GO; GO:0015267; F:channel activity; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008289; F:lipid binding; IDA:HGNC.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:HGNC.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:HGNC.
DR   GO; GO:0008635; P:activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c; IDA:HGNC.
DR   GO; GO:0097296; P:activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0006987; P:activation of signaling protein activity involved in unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0008637; P:apoptotic mitochondrial changes; IDA:HGNC.
DR   GO; GO:0006915; P:apoptotic process; NAS:UniProtKB.
DR   GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:1902262; P:apoptotic process involved in patterning of blood vessels; IEA:Ensembl.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IDA:HGNC.
DR   GO; GO:0001783; P:B cell apoptotic process; IDA:HGNC.
DR   GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl.
DR   GO; GO:0002358; P:B cell homeostatic proliferation; IEA:Ensembl.
DR   GO; GO:0002352; P:B cell negative selection; IEA:Ensembl.
DR   GO; GO:1990117; P:B cell receptor apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0045333; P:cellular respiration; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0045136; P:development of secondary sexual characteristics; IEA:Ensembl.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl.
DR   GO; GO:0032469; P:endoplasmic reticulum calcium ion homeostasis; TAS:UniProtKB.
DR   GO; GO:0010248; P:establishment or maintenance of transmembrane electrochemical gradient; IDA:HGNC.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IBA:GO_Central.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IC:BHF-UCL.
DR   GO; GO:0009566; P:fertilization; IEA:Ensembl.
DR   GO; GO:0007281; P:germ cell development; IEA:Ensembl.
DR   GO; GO:0034349; P:glial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; IEA:Ensembl.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0021854; P:hypothalamus development; IEA:Ensembl.
DR   GO; GO:0007007; P:inner mitochondrial membrane organization; IEA:Ensembl.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IDA:HGNC.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IMP:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IDA:HGNC.
DR   GO; GO:0008053; P:mitochondrial fusion; IDA:HGNC.
DR   GO; GO:0070584; P:mitochondrion morphogenesis; IEA:Ensembl.
DR   GO; GO:0002262; P:myeloid cell homeostasis; IEA:Ensembl.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0032471; P:negative regulation of endoplasmic reticulum calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0007008; P:outer mitochondrial membrane organization; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:1902512; P:positive regulation of apoptotic DNA fragmentation; IMP:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0060058; P:positive regulation of apoptotic process involved in mammary gland involution; IEA:Ensembl.
DR   GO; GO:0002904; P:positive regulation of B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0048087; P:positive regulation of developmental pigmentation; IEA:Ensembl.
DR   GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:1903896; P:positive regulation of IRE1-mediated unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1901030; P:positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:HGNC.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IDA:UniProtKB.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0048597; P:post-embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0012501; P:programmed cell death; TAS:Reactome.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0001844; P:protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0051259; P:protein oligomerization; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0033599; P:regulation of mammary gland epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:1902445; P:regulation of mitochondrial membrane permeability involved in programmed necrotic cell death; IEA:Ensembl.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IDA:HGNC.
DR   GO; GO:0006808; P:regulation of nitrogen utilization; IEA:Ensembl.
DR   GO; GO:0043497; P:regulation of protein heterodimerization activity; IPI:HGNC.
DR   GO; GO:0043496; P:regulation of protein homodimerization activity; IDA:HGNC.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IDA:BHF-UCL.
DR   GO; GO:0032976; P:release of matrix enzymes from mitochondria; IDA:HGNC.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0046688; P:response to copper ion; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0009651; P:response to salt stress; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IDA:HGNC.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:1990009; P:retinal cell apoptotic process; IMP:HGNC.
DR   GO; GO:0046666; P:retinal cell programmed cell death; IEA:Ensembl.
DR   GO; GO:0060011; P:Sertoli cell proliferation; IEA:Ensembl.
DR   GO; GO:0048515; P:spermatid differentiation; IEA:Ensembl.
DR   GO; GO:0001777; P:T cell homeostatic proliferation; IEA:Ensembl.
DR   GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0006927; P:transformed cell apoptotic process; IMP:HGNC.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR026304; BAX.
DR   InterPro; IPR002475; Bcl2-like.
DR   InterPro; IPR020717; Bcl2_BH1_motif_CS.
DR   InterPro; IPR020726; Bcl2_BH2_motif_CS.
DR   InterPro; IPR020728; Bcl2_BH3_motif_CS.
DR   InterPro; IPR026298; Blc2_fam.
DR   PANTHER; PTHR11256; PTHR11256; 1.
DR   PANTHER; PTHR11256:SF8; PTHR11256:SF8; 1.
DR   Pfam; PF00452; Bcl-2; 1.
DR   PRINTS; PR01862; BCL2FAMILY.
DR   PROSITE; PS50062; BCL2_FAMILY; 1.
DR   PROSITE; PS01080; BH1; 1.
DR   PROSITE; PS01258; BH2; 1.
DR   PROSITE; PS01259; BH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   Complete proteome; Cytoplasm; Host-virus interaction; Membrane;
KW   Mitochondrion; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Tumor suppressor.
FT   CHAIN         1    192       Apoptosis regulator BAX.
FT                                /FTId=PRO_0000143053.
FT   TRANSMEM    172    192       Helical. {ECO:0000255}.
FT   MOTIF        59     73       BH3.
FT   MOTIF        98    118       BH1.
FT   MOTIF       150    165       BH2.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000269|PubMed:19413330}.
FT   VAR_SEQ       1     78       Missing (in isoform Zeta).
FT                                {ECO:0000303|Ref.6}.
FT                                /FTId=VSP_031239.
FT   VAR_SEQ       1     19       Missing (in isoform Psi).
FT                                {ECO:0000303|PubMed:11912183}.
FT                                /FTId=VSP_031238.
FT   VAR_SEQ      12     41       GPTSSEQIMKTGALLLQGFIQDRAGRMGGE -> VSSRIEQ
FT                                GEWGGRHPSWPWTRCLRMRPPRS (in isoform
FT                                Gamma). {ECO:0000303|PubMed:8358790}.
FT                                /FTId=VSP_031234.
FT   VAR_SEQ      30     78       Missing (in isoform Delta).
FT                                {ECO:0000303|PubMed:7607685}.
FT                                /FTId=VSP_031235.
FT   VAR_SEQ      42    192       Missing (in isoform Gamma).
FT                                {ECO:0000303|PubMed:8358790}.
FT                                /FTId=VSP_031236.
FT   VAR_SEQ     125    192       LCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYF
FT                                GTPTWQTVTIFVAGVLTASLTIWKKMG -> GVKWRDLGSL
FT                                QPLPPGFKRFTCLSIPRSWDYRPCAPRCRN (in
FT                                isoform Epsilon).
FT                                {ECO:0000303|PubMed:9920818}.
FT                                /FTId=VSP_031240.
FT   VAR_SEQ     159    192       DGLLSYFGTPTWQTVTIFVAGVLTASLTIWKKMG -> VRL
FT                                LKPPHPHHRALTTAPAPPSLPPATPLGPWAFWSRSQWCPLP
FT                                IFRSSDVVYNAFSLRV (in isoform Beta).
FT                                {ECO:0000303|PubMed:8358790}.
FT                                /FTId=VSP_031237.
FT   VAR_SEQ     159    171       Missing (in isoform Sigma).
FT                                {ECO:0000303|PubMed:10772918}.
FT                                /FTId=VSP_037475.
FT   VARIANT      11     11       G -> E (in a plasmacytoma cell line).
FT                                {ECO:0000269|PubMed:9531611}.
FT                                /FTId=VAR_013575.
FT   VARIANT      39     39       G -> R (in dbSNP:rs36017265).
FT                                /FTId=VAR_047053.
FT   VARIANT      67     67       G -> R (in a T-cell acute lymphoblastic
FT                                leukemia cell line; loss of
FT                                heterodimerization with Bcl-2 or Bcl-
FT                                X(L)). {ECO:0000269|PubMed:7475270,
FT                                ECO:0000269|PubMed:9531611}.
FT                                /FTId=VAR_007809.
FT   VARIANT     108    108       G -> V (in a Burkitt lymphoma; loss of
FT                                homodimerization).
FT                                {ECO:0000269|PubMed:7475270,
FT                                ECO:0000269|PubMed:9531611}.
FT                                /FTId=VAR_013576.
FT   MUTAGEN      21     21       K->E: Reduces interaction with BCL2L11,
FT                                homooligomerization and triggering of
FT                                apoptosis. {ECO:0000269|PubMed:18948948}.
FT   MUTAGEN      74     74       M->D,E: Strongly reduced interaction with
FT                                MCL1, BCL2, BCL2L1 and BCL2L2. No effect
FT                                on cytochrome c release and subsequent
FT                                apoptosis triggered by etoposide.
FT                                {ECO:0000269|PubMed:21199865}.
FT   MUTAGEN     184    184       S->D,E,H,K: Constitutive cytoplasmic
FT                                location. {ECO:0000269|PubMed:10228148}.
FT   MUTAGEN     184    184       S->V: Constitutive mitochondrial
FT                                location. {ECO:0000269|PubMed:10228148}.
FT   TURN          2      4       {ECO:0000244|PDB:2K7W}.
FT   STRAND       10     14       {ECO:0000244|PDB:1F16}.
FT   HELIX        16     36       {ECO:0000244|PDB:4BD2}.
FT   STRAND       43     45       {ECO:0000244|PDB:1F16}.
FT   HELIX        54     72       {ECO:0000244|PDB:4BD2}.
FT   HELIX        74     82       {ECO:0000244|PDB:4BD2}.
FT   HELIX        88     99       {ECO:0000244|PDB:4BD2}.
FT   TURN        100    102       {ECO:0000244|PDB:4BD2}.
FT   HELIX       107    147       {ECO:0000244|PDB:4BD2}.
FT   HELIX       149    154       {ECO:0000244|PDB:4BD2}.
FT   TURN        155    158       {ECO:0000244|PDB:4BD2}.
FT   HELIX       159    164       {ECO:0000244|PDB:4BD2}.
FT   HELIX       171    188       {ECO:0000244|PDB:1F16}.
SQ   SEQUENCE   192 AA;  21184 MW;  6C0CDB0A7DEE4994 CRC64;
     MDGSGEQPRG GGPTSSEQIM KTGALLLQGF IQDRAGRMGG EAPELALDPV PQDASTKKLS
     ECLKRIGDEL DSNMELQRMI AAVDTDSPRE VFFRVAADMF SDGNFNWGRV VALFYFASKL
     VLKALCTKVP ELIRTIMGWT LDFLRERLLG WIQDQGGWDG LLSYFGTPTW QTVTIFVAGV
     LTASLTIWKK MG
//
